Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMI S KOMROKJI

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1942266929
CMS profile
360901
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$170,108.54

122 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMI S KOMROKJI

NPI 1942266929 · CMS profile ID 360901

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942266929?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMI S KOMROKJI, NPI 1942266929, CMS profile ID 360901. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942266929?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAMI S KOMROKJI, NPI 1942266929, CMS profile ID 360901. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942266929?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAMI S KOMROKJI, NPI 1942266929, CMS profile ID 360901, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1942266929?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

122 matching records · $170,108.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 122 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–122 of 122.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Rigel Pharmaceuticals, Inc. $6,850.0003/07/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145203347 CMS
Genentech USA, Inc. $29.8203/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133092778 CMS
Rigel Pharmaceuticals, Inc. $68.9203/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145201648 CMS
ABBVIE INC. $5,400.0002/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103136383 CMS
Rigel Pharmaceuticals, Inc. $94.6102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145199577 CMS
Rigel Pharmaceuticals, Inc. $516.8002/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145209413 CMS
Rigel Pharmaceuticals, Inc. $258.2302/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145209415 CMS
Rigel Pharmaceuticals, Inc. $350.0002/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145209417 CMS
Rigel Pharmaceuticals, Inc. $50.0002/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145209419 CMS
Rigel Pharmaceuticals, Inc. $50.0002/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145209425 CMS
Rigel Pharmaceuticals, Inc. $112.2802/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145209427 CMS
Rigel Pharmaceuticals, Inc. $55.9202/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145199575 CMS
SERVIER PHARMACEUTICALS LLC $1,020.0002/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147262797 CMS
E.R. Squibb & Sons, L.L.C. $2,580.0002/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101494324 CMS
ABBVIE INC. $675.0001/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103136381 CMS
Daiichi Sankyo Inc. $645.0001/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089444075 CMS
Daiichi Sankyo Inc. $161.2501/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089444081 CMS
Genentech USA, Inc. $132.2301/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133092782 CMS
Sumitomo Pharma America, Inc. $8,950.0001/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148876290 CMS
ABBVIE INC. $3,375.0001/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103136379 CMS
ABBVIE INC. $18.1101/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104192004 CMS
ABBVIE INC. $471.6701/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104192006 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $115,673.61 127
PY2020 $63,199.08 35
PY2021 $104,180.38 60
PY2022 $101,967.14 73
PY2023 $118,953.89 84
PY2024 $170,108.54 122
PY2025 $180,715.57 124

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,861.15 21
PY2025 Principal investigator $333,908.34 192
PY2024 Recipient $1,204.72 1
PY2024 Principal investigator $92,959.92 24
PY2023 Recipient $509.29 1
PY2023 Principal investigator $393,998.73 34
PY2022 Recipient $825.00 2
PY2022 Principal investigator $421,012.46 64
PY2021 Principal investigator $827,000.70 131
PY2020 Recipient $7,500.00 1
PY2020 Principal investigator $667,183.25 107
PY2019 Recipient $11,051.00 3
PY2019 Principal investigator $695,841.03 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

213 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,316.64 12/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1236000568
Principal investigator 1 Geron Corporation $266.00 12/18/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238897204
Principal investigator 1 Geron Corporation $266.00 12/18/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238897208
Principal investigator 1 ABBVIE INC. $2,000.00 12/15/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202416469
Principal investigator 1 Geron Corporation $266.00 12/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238897178
Principal investigator 1 Geron Corporation $266.00 12/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238897182
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,719.00 12/10/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268100
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,980.00 12/10/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268102
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,224.00 12/10/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268104
Principal investigator 1 Geron Corporation $210.00 12/08/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238897153
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $412.00 12/05/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268090
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $266.00 12/05/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268092
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $293.76 12/05/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268094
Principal investigator 1 Geron Corporation $5,009.56 12/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896954
Principal investigator 1 Geron Corporation $5,009.56 12/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896958
Principal investigator 1 Geron Corporation $176.80 12/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896962
Principal investigator 1 Geron Corporation $4,343.57 12/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896966
Principal investigator 1 Geron Corporation $58.75 12/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896970
Principal investigator 1 Geron Corporation $1,060.00 12/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896950
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,424.00 11/19/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268086
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,060.00 11/19/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268088
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $974.00 11/12/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268084
Principal investigator 1 Geron Corporation $146.88 11/05/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896853
Principal investigator 1 Geron Corporation $73.44 11/05/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896857
Principal investigator 1 Geron Corporation $2,820.16 11/05/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896861
Principal investigator 1 Geron Corporation $58.75 11/05/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896864
Principal investigator 1 Geron Corporation $2,663.76 11/05/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896868
Principal investigator 1 Geron Corporation $2,663.76 11/05/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896871
Principal investigator 1 Geron Corporation $58.75 10/31/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896483
Principal investigator 1 Geron Corporation $73.44 10/31/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896487
Principal investigator 1 Geron Corporation $146.88 10/31/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896490
Principal investigator 1 Geron Corporation $58.75 10/27/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896353
Principal investigator 1 Geron Corporation $73.44 10/27/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896357
Principal investigator 1 Geron Corporation $955.00 10/27/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896361
Principal investigator 1 Geron Corporation $636.00 10/22/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896313
Principal investigator 1 Geron Corporation $2,820.16 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896171
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896176
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896180
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896184
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896191
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896197
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896202
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896206
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896210
Principal investigator 1 Geron Corporation $2,820.16 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896214
Principal investigator 1 Geron Corporation $979.25 10/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238896218
Principal investigator 1 Geron Corporation $61.20 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896079
Principal investigator 1 Geron Corporation $4,343.57 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896084
Principal investigator 1 Geron Corporation $5,009.56 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896087
Principal investigator 1 Geron Corporation $61.20 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896091
Principal investigator 1 Geron Corporation $95.20 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896095
Principal investigator 1 Geron Corporation $523.60 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896099
Principal investigator 1 Geron Corporation $5,009.56 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896103
Principal investigator 1 Geron Corporation $5,681.25 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896107
Principal investigator 1 Geron Corporation $523.60 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896110
Principal investigator 1 Geron Corporation $61.20 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896114
Principal investigator 1 Geron Corporation $61.20 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896118
Principal investigator 1 Geron Corporation $523.60 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896122
Principal investigator 1 Geron Corporation $61.20 10/03/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896125
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,996.85 09/29/2025 Non-covered Recipient Entity
Moffitt Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235995645
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,501.76 09/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268080
Principal investigator 1 Geron Corporation $210.00 09/24/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896067
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,865.00 09/10/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268068
Principal investigator 1 Geron Corporation $266.00 08/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895986
Principal investigator 1 Geron Corporation $212.00 08/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895990
Principal investigator 1 Geron Corporation $2,595.00 08/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895993
Principal investigator 1 ABBVIE INC. $325.00 08/14/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202416361
Principal investigator 1 Geron Corporation $5,399.27 08/13/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895904
Principal investigator 1 Geron Corporation $266.00 08/08/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895896
Principal investigator 1 Geron Corporation $266.00 08/08/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895900
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,405.00 08/06/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268062
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $212.00 08/06/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268064
Principal investigator 1 Geron Corporation $73.44 08/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895873
Principal investigator 1 Geron Corporation $146.88 08/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895877
Principal investigator 1 Geron Corporation $73.44 08/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895881
Principal investigator 1 Geron Corporation $58.75 08/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895885
Principal investigator 1 Geron Corporation $146.88 08/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895888
Principal investigator 1 Geron Corporation $58.75 08/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895892
Principal investigator 1 Geron Corporation $2,823.90 08/01/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895861
Principal investigator 1 Geron Corporation $3,075.50 08/01/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895865
Principal investigator 1 Geron Corporation $266.00 08/01/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895868
Principal investigator 1 Geron Corporation $2,820.16 07/30/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895845
Principal investigator 1 Geron Corporation $2,820.16 07/30/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895849
Principal investigator 1 Geron Corporation $3,075.50 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895807
Principal investigator 1 Geron Corporation $3,075.50 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895811
Principal investigator 1 Geron Corporation $2,823.90 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895816
Principal investigator 1 Geron Corporation $10,303.25 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895820
Principal investigator 1 Geron Corporation $3,211.50 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895824
Principal investigator 1 Geron Corporation $3,197.90 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895828
Principal investigator 1 Geron Corporation $3,333.90 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895833
Principal investigator 1 Geron Corporation $2,823.90 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895837
Principal investigator 1 Geron Corporation $2,823.90 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895840
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $315.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268058
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $212.00 07/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1223268060
Principal investigator 1 Geron Corporation $210.00 07/18/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895653
Principal investigator 1 Geron Corporation $258.00 07/18/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895656
Principal investigator 1 Geron Corporation $146.88 07/09/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895638
Principal investigator 1 Geron Corporation $73.44 07/09/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895642
Principal investigator 1 Geron Corporation $58.75 07/09/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895646
Principal investigator 1 Geron Corporation $210.00 07/04/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895577
Principal investigator 1 Geron Corporation $2,820.16 06/26/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895522
Principal investigator 1 Geron Corporation $210.00 06/26/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895526
Principal investigator 1 Geron Corporation $2,820.16 06/26/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895530
Principal investigator 1 Geron Corporation $2,820.16 06/26/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895534
Principal investigator 1 Geron Corporation $210.00 06/26/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895538
Principal investigator 1 Geron Corporation $938.21 06/26/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895542
Principal investigator 1 Geron Corporation $58.75 06/23/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895422
Principal investigator 1 Geron Corporation $73.44 06/23/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895427
Principal investigator 1 Geron Corporation $146.88 06/23/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895431
Principal investigator 1 Geron Corporation $266.00 06/23/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895435
Principal investigator 1 Celgene Corporation $4,172.00 06/13/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3b, open label, single-arm rollover study to evaluate long term safety in subjects who have participated in other Luspatercept (Ace-536) clinical trials. No dispute reported 06/30/2026 1222305400
Recipient Takeda Pharmaceuticals U.S.A., Inc. $11.86 06/11/2025 Covered Recipient Physician A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions No dispute reported 06/30/2026 1223263120
Recipient Takeda Pharmaceuticals U.S.A., Inc. $29.65 06/11/2025 Covered Recipient Physician A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions No dispute reported 06/30/2026 1223263122
Recipient Takeda Pharmaceuticals U.S.A., Inc. $11.86 06/11/2025 Covered Recipient Physician A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions No dispute reported 06/30/2026 1223263124
Recipient Takeda Pharmaceuticals U.S.A., Inc. $132.02 06/11/2025 Covered Recipient Physician A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions No dispute reported 06/30/2026 1223263126
Recipient Takeda Pharmaceuticals U.S.A., Inc. $162.27 06/11/2025 Covered Recipient Physician A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions No dispute reported 06/30/2026 1223263128
Recipient Takeda Pharmaceuticals U.S.A., Inc. $12.93 06/10/2025 Covered Recipient Physician A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions No dispute reported 06/30/2026 1223263114
Recipient Takeda Pharmaceuticals U.S.A., Inc. $58.41 06/10/2025 Covered Recipient Physician A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions No dispute reported 06/30/2026 1223263116
Recipient Takeda Pharmaceuticals U.S.A., Inc. $748.13 06/10/2025 Covered Recipient Physician A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions No dispute reported 06/30/2026 1223263118
Principal investigator 1 Celgene Corporation $27,767.03 06/06/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305260
Recipient Takeda Pharmaceuticals U.S.A., Inc. $67.00 06/01/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263112
Recipient Takeda Pharmaceuticals U.S.A., Inc. $70.00 05/29/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263104
Recipient Takeda Pharmaceuticals U.S.A., Inc. $32.00 05/29/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263106
Recipient Takeda Pharmaceuticals U.S.A., Inc. $75.00 05/29/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263108
Recipient Takeda Pharmaceuticals U.S.A., Inc. $32.00 05/29/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263110
Recipient Takeda Pharmaceuticals U.S.A., Inc. $201.03 05/28/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263088
Recipient Takeda Pharmaceuticals U.S.A., Inc. $9.00 05/28/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263090
Recipient Takeda Pharmaceuticals U.S.A., Inc. $175.00 05/28/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263092
Recipient Takeda Pharmaceuticals U.S.A., Inc. $600.00 05/28/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263094
Recipient Takeda Pharmaceuticals U.S.A., Inc. $289.93 05/28/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263096
Recipient Takeda Pharmaceuticals U.S.A., Inc. $57.30 05/28/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263098
Recipient Takeda Pharmaceuticals U.S.A., Inc. $64.76 05/28/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263100
Recipient Takeda Pharmaceuticals U.S.A., Inc. $21.00 05/28/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes (MDS)(RENEW) No dispute reported 06/30/2026 1223263102
Principal investigator 1 ABBVIE INC. $190.40 05/22/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202416310
Principal investigator 1 ABBVIE INC. $250.00 05/21/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202416293
Principal investigator 1 Geron Corporation $258.00 05/21/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895227
Principal investigator 1 Geron Corporation $146.88 05/16/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895199
Principal investigator 1 Geron Corporation $73.44 05/16/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895203
Principal investigator 1 Geron Corporation $58.75 05/16/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895207
Principal investigator 1 Celgene Corporation $7,242.00 05/12/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222304485
Principal investigator 1 Geron Corporation $2,823.90 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895085
Principal investigator 1 Geron Corporation $856.80 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895090
Principal investigator 1 Geron Corporation $3,197.90 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895094
Principal investigator 1 Geron Corporation $3,211.50 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895097
Principal investigator 1 Geron Corporation $3,075.50 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895102
Principal investigator 1 Geron Corporation $3,075.50 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895106
Principal investigator 1 Geron Corporation $266.00 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895110
Principal investigator 1 Geron Corporation $2,823.90 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895114
Principal investigator 1 Geron Corporation $2,823.90 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895117
Principal investigator 1 Geron Corporation $2,823.90 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895122
Principal investigator 1 Geron Corporation $3,333.90 05/07/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895126
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894863
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894867
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894871
Principal investigator 1 Geron Corporation $938.21 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894875
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894879
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894883
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894886
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894890
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894894
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894898
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894902
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894906
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894910
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894913
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894917
Principal investigator 1 Geron Corporation $938.21 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894921
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894925
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894929
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894933
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894936
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894941
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894945
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894949
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894953
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894957
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894961
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894965
Principal investigator 1 Geron Corporation $938.21 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894969
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894972
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894976
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894981
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894984
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894988
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894991
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238894995
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895000
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895004
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895007
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895011
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895015
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895018
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895022
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895027
Principal investigator 1 Geron Corporation $938.21 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895031
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895035
Principal investigator 1 Geron Corporation $938.21 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895038
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895043
Principal investigator 1 Geron Corporation $938.21 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895047
Principal investigator 1 Geron Corporation $938.21 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895051
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895056
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895061
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895065
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895068
Principal investigator 1 Geron Corporation $2,820.16 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895071
Principal investigator 1 Geron Corporation $376.24 04/25/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895075
Principal investigator 1 Geron Corporation $266.00 04/14/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238894397
Principal investigator 1 Celgene Corporation $8,285.69 03/26/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305452
Principal investigator 1 ABBVIE INC. $795.00 02/26/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
M16-109 - A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202416207
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,670.52 02/24/2025 Non-covered Recipient Entity
Moffitt Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235995643
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,397.00 02/14/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Nave Subjec No dispute reported 06/30/2026 1236000566
Principal investigator 1 ABBVIE INC. $124.00 01/16/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
M16-109 - A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202416107
Principal investigator 1 ABBVIE INC. $600.00 01/15/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
M16-109 - A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202416099